Fangzhou Inc. has signed a Memorandum of Understanding with Novo Nordisk and will collaborate with Novo Nordisk on managing serious chronic diseases, such as diabetes and obesity.
By leveraging Novo Nordisk's expertise and innovative products in diabetes and obesity treatment, Fangzhou plans to employ its smart healthcare ecosystem and robust technology infrastructure to create a comprehensive health management service. This will include medication guidance, reminders, efficacy tracking, and health education, effectively shaping the value chain in the glucose control and weight loss sector. The aim is to shift the focus from a "disease-centered" approach to a "health-centered" model, providing patients with higher quality and more convenient one-stop healthcare services.
Dr. Xie Fangmin remarked, "We are partnering with Novo Nordisk, a leading global healthcare company, to explore AI technology and address the pain points of traditional health management. Together, we aim to deliver innovative digital solutions for managing blood sugar and weight on a global scale."
Christine Zhou said, "With the combined strengths of both companies, this collaboration will closely integrate chronic disease prevention and digital innovation technology, jointly enhancing public awareness of diabetes and obesity. It will also support the aim that the concepts of early screening, early diagnosis, and early treatment are effectively implemented within smart healthcare environments."
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!